⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
SCANBO® FEATURED IN GOVERNMENT OF BRITISH COLUMBIA'S 2026 LIFE SCIENCES ECOSYSTEM MAP
prnewswire.com
ABCL
STEM
XNCR
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
globenewswire.com
AMGN
JNJ
XNCR
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
Form 8-K
sec.gov
XNCR
Form 8-K
sec.gov
XNCR
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
businesswire.com
XNCR
TIME roept Xenco Medical uit tot een van de 100 meest invloedrijke bedrijven ter wereld van TIME en winnaar van de 2026 TIME100 Impact Award in Gezondheid
businesswire.com
XNCR
Form 8-K
sec.gov
XNCR
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME